Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Sareum Holdings

    MCap

    GBP52m

    Last close

    GBP0.37

    ▲ 0.00 (0.00%)

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    OpGen

    MCap

    USD58m

    Last close

    USD5.00

    ▲ 0.40 (8.70%)

  • Sectors

    Sectors

    View All Sectors
  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Chosa (XSAT: CHOSA)

Last close As at 26/08/2026

SEK0.73

— 0.00 (0.27%)

Market capitalisation

SEK67m

Chosa Oncology (previously RhoVac) is a Danish biotech focused on the development of iCIP, a technology consisting of a cisplatin drug response predictor and a liposomal formulation of conventional cisplatin. iCIP has demonstrated encouraging clinical proof of concept from a Phase IIb study in breast cancer patients and Chosa is now looking for strategic partnerships to progress clinical development of the technology.

Latest Insights

View More

Healthcare | edison tv

CHOSA Oncology – executive interview

Healthcare | Update

Chosa Oncology — Making headway in precision oncology

Healthcare | Update

RhoVac — On the home straight

Healthcare | Outlook

RhoVac — Phase IIb BRaVac study results in H122

Market Data

Share Price SEK0.73
Market Cap SEK67m
52-Week High SEK2.20
52-Week Low SEK0.51
% Change 1M (15.3)
% Change 6M (14.4)
% Change 12M (14.9)
Ave. Daily Volume 1yr 69,612
Visit Website

Sector

Healthcare

Equity Analyst

Key Management

  • Claus Frisenberg Pedersen

    CFO

  • Neil Goldsmith

    Chairman

  • Peter Buhl Jensen

    CEO

Share Price Chart

Update

Healthcare

RhoVac — Funded to execute Phase IIb study as planned

Initiation

Healthcare

RhoVac — Stopping metastasis in its tracks